Urgent: Deadline Approaching for Sage Therapeutics Investors
If you’ve invested in Sage Therapeutics, Inc., now's the time to act. A significant deadline is nearing for a class action lawsuit, with October 28 being the cutoff for filing a lead plaintiff motion. Many investors are feeling a sense of urgency to safeguard their investments. This lawsuit targets shareholders who bought Sage Therapeutics securities during a specific timeframe.
What the Class Action Is About
This class action lawsuit focuses on those who acquired Sage Therapeutics, Inc. (NASDAQ: SAGE) shares within certain dates. Recent filings indicate that individuals who suffered financial losses due to the company's activities during this time are encouraged to join the lawsuit.
Why Is There a Lawsuit?
The foundation of the lawsuit stems from a series of letdowns from Sage Therapeutics. Investors were alarmed by the company's announcement regarding the FDA’s reply to their New Drug Application for zuranolone. On August 4, it became clear that while zuranolone was approved for postpartum depression, the application for treating major depressive disorder received a complete response letter, meaning further studies were necessary. In response, Sage's stock price dropped sharply, highlighting the market's reaction to the news.
Additional Challenges
In April of the following year, another setback occurred when Sage reported that the Phase 2 study for SAGE-718 failed to show significant positive results. This news further contributed to a noticeable decline in stock price, underscoring the persistent hurdles the company continues to face.
Effects on Shareholders
The string of negative disclosures from Sage has led to considerable losses for numerous investors. The lawsuit asserts that the company’s leadership made materially false and misleading statements about its products' effectiveness and development timelines, which ultimately misled shareholders regarding the company’s future prospects.
What Investors Should Do Next
If you're a shareholder who's experienced losses due to these issues with Sage Therapeutics, it’s essential to explore your legal options. Consider reaching out to legal experts who specialize in this area to discuss how you can get involved in the class action lawsuit. By providing your details, you could join other investors in the pursuit of seeking potential recovery.
Contact Information
If you're looking to learn more about your rights, you can connect with legal representatives at Glancy Prongay & Murray LLP for further assistance. Additionally, visiting the firm's website may offer more information on the next steps to take.
Frequently Asked Questions
What is the deadline for joining the class action?
The deadline to file a lead plaintiff motion is October 28, 2024.
Who can join the class action lawsuit?
Any investor who purchased Sage Therapeutics securities during the specified class period may join the lawsuit.
What claims are being made in the lawsuit?
The lawsuit claims that Sage Therapeutics misled investors about the effectiveness of its drugs and failed to disclose significant adverse information.
How has the stock price been affected?
The stock price has experienced substantial declines coinciding with negative announcements, resulting in major losses for investors.
What should I do if I want to participate?
Interested investors should collect their purchase records and consult a legal representative to explore their options.
